X0206 3 2023-10-27 0 0001124105 CATALYST BIOSCIENCES, INC. CBIO 0001958461 GNI Group Ltd. NIHONBASHI-HONCHO YS BLDG 3F 2-2-2 NIHONBASHI-HONCHO, CHUO-KU TOKYO M0 103-0023 JAPAN true 0001973229 GNI USA, Inc. 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130 true Common Stock 6266521 I See footnote Series X Convertible Preferred Stock Common Stock 123400000 I See footnote These securities are held by GNI USA, Inc., a Delaware corporation ("GNI USA"), which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA. Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022). The Preferred Stock has no expiration date. Exhibit 24.1 - Power of Attorney /s/ Branden Berns, as attorney-in-fact for GNI Group Ltd. 2023-10-27 /s/ Branden Berns, as attorney-in-fact for GNI USA, Inc. 2023-10-27